2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 min sitten⚖️ THE TAX CASE: THE DRAFT THAT PRACTICALLY DECIDES — WHAT THE 98%-STATISTIC MEANS Nykode announced on August 26th that the secretariat of the Tax Appeals Board has sent a draft recommendation which recommends FULL APPROVAL in the tax case. Upon final decision in line with the draft, the company will receive back 325 MNOK plus interest. The market reacted with a spike to 5,2 kr — and then faded to negative. I believe the market is misinterpreting this news, and here's why. 📌 BACKGROUND (30 SECONDS) The Genentech agreement in 2020 gave Nykode an upfront of USD 200M. The dispute: The Tax Administration believed the entire amount should be recognized as income in 2020; Nykode booked it to the profit and loss account (periodization over several years, cf. tax law § 14-53). The Tax Administration maintained its position in October 2023, Nykode paid 325 MNOK under protest (mandatory) and appealed to the Tax Appeals Board. 🎯 WHY "DRAFT" IS PRACTICALLY THE ANSWER The word "draft" makes this sound preliminary. The statistics say otherwise: 🔹 The Tax Appeals Board deviates from the secretariat's recommendation in only 2% of cases (source 3) 🔹 The remaining comment round belongs to NYKODE — the party that won the draft. They do not protest their own victory 🔹 The Tax Office's counterarguments are already in the case documents — and lost in the secretariat's assessment Procedurally remaining: final recommendation → decision by the board (large division). The company expects this within two months, i.e., by October. My assessment of the probability of final approval: ~90-95%. The residual risk is real but small: (1) drafts can in rare cases be revised at the initiative of the board leader, (2) the state has a narrow right to sue after a decision (tax enforcement law § 15-2, used extremely rarely), (3) the timeline has slipped before. 💰 WHAT 325 MNOK + INTEREST ACTUALLY MEANS The cash value is ~1 kr/share. But the effective value is greater: 🔹 RUNWAY: From "into 2028" to "into 2029" (source 1). Abili-T interim data is expected 2027 (12-15 months from first patient dosed May 2026). With the tax money, the company reaches the catalyst with a solid margin — WITHOUT them, the runway landed tightly at the interim time 🔹 DILUTION RISK OFF THE TABLE: The scenario "share issue at a weak price before data" — the structural concern since Q1 — is largely eliminated 🔹 NEGOTIATING POSITION: After Moderna/MSD's positive Phase 3 in melanoma (first Phase 3 success for individualized cancer vaccine ever) partner interest for VB10.NEO is likely. A company with cash until 2029 can say no to bad terms. A company in time pressure cannot 📉 WHY DIDN'T THE SHARE PRICE REACT MORE? Two explanations, probably both true: 1️⃣ Parts of the market read "draft" as "uncertain" and price it as a 50/50 that is still pending. The board's statistics are unknown to most — the information asymmetry is real 2️⃣ Something was already priced in: the company has booked the amount as a receivable in the balance sheet since 2023 (source 1) — a revised IFRS assessment that requires victory to be considered probable. Those who followed knew this If explanation 1 dominates, the gap will gradually close towards the decision. ⚠️ WHAT THIS IS NOT This is not clinical news. The Abi-suva thesis still stands and falls with Abili-T (interim 2027) — the tax case removes financing risk around the thesis, it does not prove the thesis. 1 kr/share in cash does not change whether the vaccine works. 📅 NEXT CATALYSTS 🔹 By October: Final decision by the Tax Appeals Board 🔹 H2 2026: Possible VB10.NEO partner news in the wake of Moderna validation 🔹 After summer: Board decision on clinical candidate for the tolerance platform 🔹 2027: Abili-T interim data — the main catalyst 📎 SOURCES 1. Nykode Q1 2026-report (runway, receivable USD 33,3M, tax case status): nykode.com/wp-content/uploads/2026/05/260527-Nykode-Quarterly-Report-Q1-2026.pdf 2. Stock exchange announcement 26.08.2026 (draft recommendation, 325 MNOK + interest, decision expected within two months): newsweb.oslobors.no/message/680878 3. Finansavisen 08.02.2025 "The Tax Appeals Board – a miserable success" (2% deviation statistics, approval statistics large division): finansavisen.no/skatt/2025/02/08/8239604 4. Finansavisen 23.10.2023 (case background, 330 MNOK, disagreement on profit/loss account): finansavisen.no/helse/2023/10/23/8048699 5. Merck/Moderna press release 19.08.2026 (INTerpath-001 Phase 3 positive) The probability assessment (~90-95%) and the interpretation of the market reaction are own assessments based on the sources above. Source: Own assessment. Not financial advice.
·1 t sittenABG raises to 7.0kr
Ref FA Nykode Therapeutics reported a loss of 7.2 million dollars in the second quarter, compared to a profit of 0.9 million dollars in the same period last year. In a draft from the secretariat of the Tax Appeals Board, it is recommended that Nykode Therapeutics be upheld in the tax case the company has with the Norwegian Tax Administration regarding the repayment of 325 million kroner, plus interest, Nykode reports. The share rose 0.9 percent to 4.60 kroner.
·13 t sittenDo you think the stock will rise tomorrow?
·15 t sittenI actually view my investment in Nykode as a long-term option towards 2029. I don't need to know when or if a partnership agreement will come. The interesting thing is that Nykode has several shots on goal: VB10.NEO and partnering, Abili-T-data, NeoSELECT/data and ASIT. With a positive final outcome in the tax case, they will also get 325 mill. + interest back and runway until 2029. For me, the case is therefore about something quite simple: I believe the probability that at least one of these options truly hits before capital becomes a problem, is greater than what today's valuation suggests. And in biotech, one direct hit can be enough.
Precise and very good 👍 / if we had been back to before 2007 (DMA), the stock would probably have been much higher.
·17 t sittenThe article is from today, before the tax news of course, but I thought it was good reading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 min sitten⚖️ THE TAX CASE: THE DRAFT THAT PRACTICALLY DECIDES — WHAT THE 98%-STATISTIC MEANS Nykode announced on August 26th that the secretariat of the Tax Appeals Board has sent a draft recommendation which recommends FULL APPROVAL in the tax case. Upon final decision in line with the draft, the company will receive back 325 MNOK plus interest. The market reacted with a spike to 5,2 kr — and then faded to negative. I believe the market is misinterpreting this news, and here's why. 📌 BACKGROUND (30 SECONDS) The Genentech agreement in 2020 gave Nykode an upfront of USD 200M. The dispute: The Tax Administration believed the entire amount should be recognized as income in 2020; Nykode booked it to the profit and loss account (periodization over several years, cf. tax law § 14-53). The Tax Administration maintained its position in October 2023, Nykode paid 325 MNOK under protest (mandatory) and appealed to the Tax Appeals Board. 🎯 WHY "DRAFT" IS PRACTICALLY THE ANSWER The word "draft" makes this sound preliminary. The statistics say otherwise: 🔹 The Tax Appeals Board deviates from the secretariat's recommendation in only 2% of cases (source 3) 🔹 The remaining comment round belongs to NYKODE — the party that won the draft. They do not protest their own victory 🔹 The Tax Office's counterarguments are already in the case documents — and lost in the secretariat's assessment Procedurally remaining: final recommendation → decision by the board (large division). The company expects this within two months, i.e., by October. My assessment of the probability of final approval: ~90-95%. The residual risk is real but small: (1) drafts can in rare cases be revised at the initiative of the board leader, (2) the state has a narrow right to sue after a decision (tax enforcement law § 15-2, used extremely rarely), (3) the timeline has slipped before. 💰 WHAT 325 MNOK + INTEREST ACTUALLY MEANS The cash value is ~1 kr/share. But the effective value is greater: 🔹 RUNWAY: From "into 2028" to "into 2029" (source 1). Abili-T interim data is expected 2027 (12-15 months from first patient dosed May 2026). With the tax money, the company reaches the catalyst with a solid margin — WITHOUT them, the runway landed tightly at the interim time 🔹 DILUTION RISK OFF THE TABLE: The scenario "share issue at a weak price before data" — the structural concern since Q1 — is largely eliminated 🔹 NEGOTIATING POSITION: After Moderna/MSD's positive Phase 3 in melanoma (first Phase 3 success for individualized cancer vaccine ever) partner interest for VB10.NEO is likely. A company with cash until 2029 can say no to bad terms. A company in time pressure cannot 📉 WHY DIDN'T THE SHARE PRICE REACT MORE? Two explanations, probably both true: 1️⃣ Parts of the market read "draft" as "uncertain" and price it as a 50/50 that is still pending. The board's statistics are unknown to most — the information asymmetry is real 2️⃣ Something was already priced in: the company has booked the amount as a receivable in the balance sheet since 2023 (source 1) — a revised IFRS assessment that requires victory to be considered probable. Those who followed knew this If explanation 1 dominates, the gap will gradually close towards the decision. ⚠️ WHAT THIS IS NOT This is not clinical news. The Abi-suva thesis still stands and falls with Abili-T (interim 2027) — the tax case removes financing risk around the thesis, it does not prove the thesis. 1 kr/share in cash does not change whether the vaccine works. 📅 NEXT CATALYSTS 🔹 By October: Final decision by the Tax Appeals Board 🔹 H2 2026: Possible VB10.NEO partner news in the wake of Moderna validation 🔹 After summer: Board decision on clinical candidate for the tolerance platform 🔹 2027: Abili-T interim data — the main catalyst 📎 SOURCES 1. Nykode Q1 2026-report (runway, receivable USD 33,3M, tax case status): nykode.com/wp-content/uploads/2026/05/260527-Nykode-Quarterly-Report-Q1-2026.pdf 2. Stock exchange announcement 26.08.2026 (draft recommendation, 325 MNOK + interest, decision expected within two months): newsweb.oslobors.no/message/680878 3. Finansavisen 08.02.2025 "The Tax Appeals Board – a miserable success" (2% deviation statistics, approval statistics large division): finansavisen.no/skatt/2025/02/08/8239604 4. Finansavisen 23.10.2023 (case background, 330 MNOK, disagreement on profit/loss account): finansavisen.no/helse/2023/10/23/8048699 5. Merck/Moderna press release 19.08.2026 (INTerpath-001 Phase 3 positive) The probability assessment (~90-95%) and the interpretation of the market reaction are own assessments based on the sources above. Source: Own assessment. Not financial advice.
- ·1 t sittenABG raises to 7.0krRef FA Nykode Therapeutics reported a loss of 7.2 million dollars in the second quarter, compared to a profit of 0.9 million dollars in the same period last year. In a draft from the secretariat of the Tax Appeals Board, it is recommended that Nykode Therapeutics be upheld in the tax case the company has with the Norwegian Tax Administration regarding the repayment of 325 million kroner, plus interest, Nykode reports. The share rose 0.9 percent to 4.60 kroner.
- ·13 t sittenDo you think the stock will rise tomorrow?
- ·15 t sittenI actually view my investment in Nykode as a long-term option towards 2029. I don't need to know when or if a partnership agreement will come. The interesting thing is that Nykode has several shots on goal: VB10.NEO and partnering, Abili-T-data, NeoSELECT/data and ASIT. With a positive final outcome in the tax case, they will also get 325 mill. + interest back and runway until 2029. For me, the case is therefore about something quite simple: I believe the probability that at least one of these options truly hits before capital becomes a problem, is greater than what today's valuation suggests. And in biotech, one direct hit can be enough.Precise and very good 👍 / if we had been back to before 2007 (DMA), the stock would probably have been much higher.
- ·17 t sittenThe article is from today, before the tax news of course, but I thought it was good reading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 min sitten⚖️ THE TAX CASE: THE DRAFT THAT PRACTICALLY DECIDES — WHAT THE 98%-STATISTIC MEANS Nykode announced on August 26th that the secretariat of the Tax Appeals Board has sent a draft recommendation which recommends FULL APPROVAL in the tax case. Upon final decision in line with the draft, the company will receive back 325 MNOK plus interest. The market reacted with a spike to 5,2 kr — and then faded to negative. I believe the market is misinterpreting this news, and here's why. 📌 BACKGROUND (30 SECONDS) The Genentech agreement in 2020 gave Nykode an upfront of USD 200M. The dispute: The Tax Administration believed the entire amount should be recognized as income in 2020; Nykode booked it to the profit and loss account (periodization over several years, cf. tax law § 14-53). The Tax Administration maintained its position in October 2023, Nykode paid 325 MNOK under protest (mandatory) and appealed to the Tax Appeals Board. 🎯 WHY "DRAFT" IS PRACTICALLY THE ANSWER The word "draft" makes this sound preliminary. The statistics say otherwise: 🔹 The Tax Appeals Board deviates from the secretariat's recommendation in only 2% of cases (source 3) 🔹 The remaining comment round belongs to NYKODE — the party that won the draft. They do not protest their own victory 🔹 The Tax Office's counterarguments are already in the case documents — and lost in the secretariat's assessment Procedurally remaining: final recommendation → decision by the board (large division). The company expects this within two months, i.e., by October. My assessment of the probability of final approval: ~90-95%. The residual risk is real but small: (1) drafts can in rare cases be revised at the initiative of the board leader, (2) the state has a narrow right to sue after a decision (tax enforcement law § 15-2, used extremely rarely), (3) the timeline has slipped before. 💰 WHAT 325 MNOK + INTEREST ACTUALLY MEANS The cash value is ~1 kr/share. But the effective value is greater: 🔹 RUNWAY: From "into 2028" to "into 2029" (source 1). Abili-T interim data is expected 2027 (12-15 months from first patient dosed May 2026). With the tax money, the company reaches the catalyst with a solid margin — WITHOUT them, the runway landed tightly at the interim time 🔹 DILUTION RISK OFF THE TABLE: The scenario "share issue at a weak price before data" — the structural concern since Q1 — is largely eliminated 🔹 NEGOTIATING POSITION: After Moderna/MSD's positive Phase 3 in melanoma (first Phase 3 success for individualized cancer vaccine ever) partner interest for VB10.NEO is likely. A company with cash until 2029 can say no to bad terms. A company in time pressure cannot 📉 WHY DIDN'T THE SHARE PRICE REACT MORE? Two explanations, probably both true: 1️⃣ Parts of the market read "draft" as "uncertain" and price it as a 50/50 that is still pending. The board's statistics are unknown to most — the information asymmetry is real 2️⃣ Something was already priced in: the company has booked the amount as a receivable in the balance sheet since 2023 (source 1) — a revised IFRS assessment that requires victory to be considered probable. Those who followed knew this If explanation 1 dominates, the gap will gradually close towards the decision. ⚠️ WHAT THIS IS NOT This is not clinical news. The Abi-suva thesis still stands and falls with Abili-T (interim 2027) — the tax case removes financing risk around the thesis, it does not prove the thesis. 1 kr/share in cash does not change whether the vaccine works. 📅 NEXT CATALYSTS 🔹 By October: Final decision by the Tax Appeals Board 🔹 H2 2026: Possible VB10.NEO partner news in the wake of Moderna validation 🔹 After summer: Board decision on clinical candidate for the tolerance platform 🔹 2027: Abili-T interim data — the main catalyst 📎 SOURCES 1. Nykode Q1 2026-report (runway, receivable USD 33,3M, tax case status): nykode.com/wp-content/uploads/2026/05/260527-Nykode-Quarterly-Report-Q1-2026.pdf 2. Stock exchange announcement 26.08.2026 (draft recommendation, 325 MNOK + interest, decision expected within two months): newsweb.oslobors.no/message/680878 3. Finansavisen 08.02.2025 "The Tax Appeals Board – a miserable success" (2% deviation statistics, approval statistics large division): finansavisen.no/skatt/2025/02/08/8239604 4. Finansavisen 23.10.2023 (case background, 330 MNOK, disagreement on profit/loss account): finansavisen.no/helse/2023/10/23/8048699 5. Merck/Moderna press release 19.08.2026 (INTerpath-001 Phase 3 positive) The probability assessment (~90-95%) and the interpretation of the market reaction are own assessments based on the sources above. Source: Own assessment. Not financial advice.
- ·1 t sittenABG raises to 7.0krRef FA Nykode Therapeutics reported a loss of 7.2 million dollars in the second quarter, compared to a profit of 0.9 million dollars in the same period last year. In a draft from the secretariat of the Tax Appeals Board, it is recommended that Nykode Therapeutics be upheld in the tax case the company has with the Norwegian Tax Administration regarding the repayment of 325 million kroner, plus interest, Nykode reports. The share rose 0.9 percent to 4.60 kroner.
- ·13 t sittenDo you think the stock will rise tomorrow?
- ·15 t sittenI actually view my investment in Nykode as a long-term option towards 2029. I don't need to know when or if a partnership agreement will come. The interesting thing is that Nykode has several shots on goal: VB10.NEO and partnering, Abili-T-data, NeoSELECT/data and ASIT. With a positive final outcome in the tax case, they will also get 325 mill. + interest back and runway until 2029. For me, the case is therefore about something quite simple: I believe the probability that at least one of these options truly hits before capital becomes a problem, is greater than what today's valuation suggests. And in biotech, one direct hit can be enough.Precise and very good 👍 / if we had been back to before 2007 (DMA), the stock would probably have been much higher.
- ·17 t sittenThe article is from today, before the tax news of course, but I thought it was good reading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt